-
Dec 31, 2024 | 
respiratory-research.biomedcentral.com | Athol U Wells |Ayodeji Adegunsoye |Vincent Cottin |Sonye Danoff |Anand Devaraj |Kevin Flaherty | +7 more
Surveys were completed between March 2022 and July 2023. The international guideline on the definition of PPF [1] was published between distribution of the first and second rounds of the survey. The first survey was sent to 405 physicians in 32 countries and completed by 207, of whom 131 completed the second round and 94 completed the third round. The clinical experience of the respondents is summarised in Table S1 in Additional file 1.
-
Dec 23, 2024 | 
acrjournals.onlinelibrary.wiley.com | Elizabeth R Volkmann |Holly Wilhalme |Donald Tashkin |Jonathan Goldin |Alana Haussmann |Masataka Kuwana | +2 more
Supporting Information Filename Description acr25485-sup-0001-Disclosureform.pdfPDF document, 671.5 KB Disclosure Form acr25485-sup-0002-supinfo.docxWord 2007 document , 331.1 KB Supporting Information
-
Nov 4, 2024 | 
acrjournals.onlinelibrary.wiley.com | Elizabeth R Volkmann
Corresponding Author Elizabeth R. Volkmann MD, MS Department of Medicine, University of California, Los Angeles, David Geffen School of Medicine Corresponding author: Elizabeth R. Volkmann, MD, MS, 1000 Veteran Ave. Ste 32-59, Los Angeles, CA 90095, Email: [email protected], Phone: 310-825-2448, Fax: 310-206-5088 Contribution: Conceptualization, Funding acquisition, Project administration, Resources, Writing - original draft, Writing - review & editingSearch for more papers by this author
-
May 13, 2024 | 
hmpgloballearningnetwork.com | Elizabeth R Volkmann
White Papers Log in or register to view. IPF is a chronic lung disease characterized by irreversible scarring and lung fibrosis, leading to decreased lung function over time. Prompt diagnosis is crucial for early intervention, but challenges in recognizing IPF often delay diagnosis until irreversible lung damage occurs.
-
May 10, 2024 | 
hmpgloballearningnetwork.com | Elizabeth R Volkmann
What Is Idiopathic Pulmonary Fibrosis?
-
May 7, 2024 | 
digitalcommons.library.tmc.edu | Elizabeth R Volkmann |Holly Wilhalme |Shervin Assassi |Jonathan Goldin
OBJECTIVE: Progressive pulmonary fibrosis (PPF) is the leading cause of death in systemic sclerosis (SSc). This study aimed to develop a clinical prediction nomogram using clinical and biological data to assess risk of PPF among patients receiving treatment of SSc-related interstitial lung disease (SSc-ILD). METHODS: Patients with SSc-ILD who participated in the Scleroderma Lung Study II (SLS II) were randomized to treatment with either mycophenolate mofetil (MMF) or cyclophosphamide (CYC).
-
May 7, 2024 | 
digitalcommons.library.tmc.edu | Elizabeth R Volkmann |Virginia Steen |Ning Li |Michael Roth
OBJECTIVE: To evaluate short- and long-term outcomes of African American (AA) participants of Scleroderma Lung Studies (SLS) I and II. METHODS: SLS I randomized 158 participants with systemic sclerosis-interstitial lung disease (SSc-ILD) to 1 year of oral cyclophosphamide (CYC) versus placebo. SLS II randomized 142 participants with SSc-ILD to 1 year of oral CYC followed by 1 year of placebo versus 2 years of mycophenolate (MMF).
-
May 7, 2024 | 
digitalcommons.library.tmc.edu | Elizabeth R Volkmann |Donald Tashkin |Michael Roth |Ning Li
OBJECTIVE: To investigate the prevalence of the MUC5B promoter variant rs35705950 in patients with systemic sclerosis-interstitial lung disease (SSc-ILD) and whether its presence predicts response to immunosuppression with cyclophosphamide (CYC) and mycophenolate (MMF). METHODS: SSc-ILD patients who participated in Scleroderma Lung Study (SLS) II (MMF versus CYC) were included in this study (N = 142).
-
Feb 13, 2024 | 
healio.com | Isabella Hornick |Kristen Dowd |Elizabeth R Volkmann
Elizabeth Volkmann, MD, MS An individual living with ILD experiences daily symptoms (eg, cough, dyspnea, exercise intolerance, fatigue) that uniquely affect their quality of life and overall well-being. While both approved and non-approved therapies modify the course of lung function in patients with ILD, few therapies are proven to improve these daily symptoms.
-
Nov 25, 2023 | 
gazettenet.com | Elizabeth R Volkmann
Now that our first frost has brought our sweet autumn weather to an end, the colorful leaves that delivered such joy have lost their grasp and fluttered to the ground. Browned, dried and litter-like, they invite our immediate impulse to mow, mulch, bag and blow them out of sight. But wait!The leaves that once pulled sunlight into growing trees, protected nesters, provided shade, and put on a colorful show before dancing to the ground are not done with their life-giving mission.
